COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES

Influenza and Other Respiratory Viruses Pub Date : 2025-05-21 DOI:10.1111/irv.70120

Charlotte Laniece Delaunay, Nuno Verdasca, Susana Monge, Lisa Domegan, Noémie Sève, Silke Buda, Adam Meijer, Héloïse Lucaccioni, Miriam López Torrijos, Adele McKenna, Vincent Enouf, Ralf Dürrwald, Eline In't Velt, Mª Ángel de Valcárcel Laiglesia, Charlene Bennett, Shirley Masse, Annika Erdwiens, Mariette Hooiveld, Ivan Mlinarić, Gergő Túri, Ana Paula Rodrigues, Iván Martínez-Baz, Mihaela Lazar, Neus Latorre-Margalef, Vitor Borges, Marlena Kaczmarek, Sabrina Bacci, Esther Kissling, European primary care VE group

{"title":"COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024–January 2025, VEBIS Primary Care Network","authors":"Charlotte Laniece Delaunay, Nuno Verdasca, Susana Monge, Lisa Domegan, Noémie Sève, Silke Buda, Adam Meijer, Héloïse Lucaccioni, Miriam López Torrijos, Adele McKenna, Vincent Enouf, Ralf Dürrwald, Eline In't Velt, Mª Ángel de Valcárcel Laiglesia, Charlene Bennett, Shirley Masse, Annika Erdwiens, Mariette Hooiveld, Ivan Mlinarić, Gergő Túri, Ana Paula Rodrigues, Iván Martínez-Baz, Mihaela Lazar, Neus Latorre-Margalef, Vitor Borges, Marlena Kaczmarek, Sabrina Bacci, Esther Kissling, European primary care VE group","doi":"10.1111/irv.70120","DOIUrl":null,"url":null,"abstract":"<p>We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34–85) overall, 73% (95% CI: 21–94) and 54% (95% CI: −3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33–86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 5","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70120","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70120","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

We estimated the effectiveness of 2024/25 COVID-19 vaccination against medically attended SARS-CoV-2 infection in Europe, among target groups. We included 3204 patients (8/139 cases vaccinated: 6%; 517/3065 controls vaccinated: 17%) from a multicentre, test-negative design study at primary care level. Vaccine effectiveness was 66% (95% CI: 34–85) overall, 73% (95% CI: 21–94) and 54% (95% CI: −3 to 83) in the first and second months post-vaccination, respectively. Overall vaccine effectiveness was 67% (95% CI: 33–86) among older adults (≥ 60 or ≥ 65 years). This relatively high COVID-19 VE (compared with previous seasons), as well as trends by time since vaccination, should be confirmed with additional data, as sample size was low.

查看原文本刊更多论文

2019年10月- 2025年1月欧洲目标人群COVID-19疫苗对有症状的SARS-CoV-2感染的有效性，VEBIS初级保健网络

我们在欧洲的目标人群中估计了2024/25年COVID-19疫苗接种对医学上参加的SARS-CoV-2感染的有效性。我们纳入了3204例患者(8/139例接种疫苗：6%；517/3065名接种疫苗的对照组：17%)，来自初级保健水平的多中心阴性试验设计研究。总体而言，疫苗有效性为66% (95% CI: 34-85)，接种后第一个月和第二个月分别为73% （95% CI: 21-94）和54% （95% CI: - 3至83）。在老年人（≥60岁或≥65岁）中，总体疫苗有效性为67% （95% CI: 33-86）。由于样本量较低，这一相对较高的COVID-19 VE（与前几个季节相比）以及自接种疫苗以来的时间趋势应通过其他数据得到证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.